Teva Pharmaceutical (TEVA) Tops Q4 EPS by 1c

Teva Pharmaceutical (NASDAQ: TEVA) reported Q4 EPS of $1.59, $0.01 better than the analyst estimate of $1.58. Revenue for the quarter came in at $5.68 billion versus the consensus estimate of $5.61 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Star Equity to acquire Harte Hanks for $5.00 per share